BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 
 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai Fosun Pharmaceutical Ind
 ustrial Development Co. Ltd.'s drugs run\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06858618-3078@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:FCN-338: Phase 2 readout est. (NCT06858618)
DESCRIPTION:FCN-338\, phase 2.\nStudy: FCN-338 in Combination With Azacitid
 ine or Chemotherapy in Myeloid Neoplasms\nEstimated primary completion: 1 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fcn-33
 8#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 858618
URL:https://assetmemo.bio/drug/fcn-338#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07004075-7648@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Luvometinib: Phase 3 readout est. (NCT07004075)
DESCRIPTION:Luvometinib\, phase 3\, Glioma.\nStudy: FCN-159 Monotherapy Ver
 sus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Pa
 tients With BRAF Alteration\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/luvometinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07004075
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487519-2161@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07487519)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: Phase II Study of HLX43 Monother
 apy or Combined With Immune Checkpoint Inhibitors in Patients With Locally
  Advanced\, Recurrent\, or Metastatic Triple-negative Breast Cancer.\nEsti
 mated primary completion: 15 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/serplulimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07487519
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2161@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07253142)
DESCRIPTION:Serplulimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab i
 n Subjects With Advanced Lung Cancer\nEstimated primary completion: 18 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07253
 142
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358585-2161@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Serplulimab: Phase 1/2 readout est. (NCT07358585)
DESCRIPTION:Serplulimab\, phase 1/2.\nStudy: A Phase Ib/II Study to Evaluat
 e HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Me
 tastatic Colorectal Cancer\nEstimated primary completion: 28 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07358585
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857279-2161@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Serplulimab: Phase 2 readout est. (NCT06857279)
DESCRIPTION:Serplulimab\, phase 2.\nStudy: A Phase II Clinical Study to Eva
 luate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamou
 s Cell Carcinoma\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06857279
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562581-7648@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Luvometinib: Phase 2 readout est. (NCT07562581)
DESCRIPTION:Luvometinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC\
 nEstimated primary completion: June 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/luvometinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07562581
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024394-7648@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20290923
DTEND;VALUE=DATE:20290924
SUMMARY:Luvometinib: Phase 1/2 readout est. (NCT07024394)
DESCRIPTION:Luvometinib\, phase 1/2.\nStudy: Follow-up Study to Evaluate th
 e Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibro
 matosis Type 1\nEstimated primary completion: 23 September 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/luvometinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07024394
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-2161@assetmemo.bio
DTSTAMP:20261121T010014Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Serplulimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplul
 imab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pe
 mbrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous 
 Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
